ID   TOV-3133G
AC   CVCL_4064
DR   cancercelllines; CVCL_4064
DR   GEO; GSM2475010
DR   Wikidata; Q54972815
RX   PubMed=22585861;
RX   PubMed=22931248;
RX   PubMed=28273451;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=TOV-3133G
CC   Doubling time: 2.70 +- 0.15 days (PubMed=22931248).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson A.-M.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): PubMed=22585861; Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 13
ST   D16S539: 13
ST   D18S51: 16,18
ST   D19S433: 13,14
ST   D21S11: 30,32.2
ST   D2S1338: 17,25
ST   D3S1358: 14,15
ST   D5S818: 12
ST   D7S820: 8,12
ST   D8S1179: 13,15
ST   FGA: 19
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_9T15 ! OV-3133(R)
OI   CVCL_9T16 ! OV-3133(R2)
OI   CVCL_9T19 ! TOV-3133D
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 16
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//